News & Press

14.08.2018

New project granted

Regensburg, 2018-08-14: New project granted: The Wagner lab will be partner in the project "Clinical trial of a DIOS Trivalent Haemorrhagic Fever Vaccine" (HFVac3). Based on the excellent outcomes of the two predecessor projects EVAC and Tri-LEMVac, the funding organization Innovate UK decided to support the 2nd stage of the project, coordinated by Prof. Jonathan Heeney of the University of Cambridge and Head of DIOSynVax Ltd., which will develop an MVA-based vaccine candidate against three viral hemorrhagic fevers (Lassa, Ebola, and Marburg virus) toward the clinic, including generation of the MVA-seed virus, GMP-manufacturing, and initiation of a phase I clinical trial. The Wagner lab contribution to the project encompasses the generation and characterization of the MVA vaccine candidate vector suitable for GMP manufacturing. For more information, click here.

Meetings

Upcoming Meetings
> more

Jobs

We permanently offer several opportunities for students to conduct research projects in the context of `Forschungs- und Schwerpunktpraktika┬┤.
> more